Rexahn Pharmaceuticals (RNN) PT Set at $17.00 by HC Wainwright

Share on StockTwits

Rexahn Pharmaceuticals (NYSEAMERICAN:RNN) has been given a $17.00 price target by equities research analysts at HC Wainwright in a note issued to investors on Thursday. The brokerage presently has a “buy” rating on the stock.

The analysts wrote, “Valuation and risks to price target achievement. We reiterate our Buy rating but are lowering our price target to $17 from $19.50. The factors impacting our valuation include: (1) change to base year; (2) adjustment to fully diluted share count of of October 2018 equity raise; and (3) increasing our chance of success for RX-3117 in first-line pancreatic cancer from 20% to 25%. Our target is based on our clinical net present value (NPV) model, which is currently driven by the company’s two lead assets, RX-3117, and RX-5902 (Supinoxin).””

Several other equities analysts also recently commented on the company. Ifs Securities upgraded Rexahn Pharmaceuticals from an “outperform” rating to a “strong-buy” rating in a research report on Thursday, October 4th. B. Riley set a $8.00 target price on Rexahn Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, August 13th. Zacks Investment Research upgraded Rexahn Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.75 price objective for the company in a research report on Friday, August 10th. Finally, Brookline Cap M restated a “buy” rating on shares of Rexahn Pharmaceuticals in a research report on Tuesday, November 27th. Three equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. Rexahn Pharmaceuticals has a consensus rating of “Buy” and an average price target of $8.75.

Rexahn Pharmaceuticals stock opened at $1.10 on Thursday. Rexahn Pharmaceuticals has a 12 month low of $1.03 and a 12 month high of $2.70.

Rexahn Pharmaceuticals (NYSEAMERICAN:RNN) last posted its earnings results on Monday, November 5th. The company reported ($0.17) EPS for the quarter, meeting the consensus estimate of ($0.17).

Rexahn Pharmaceuticals Company Profile

Rexahn Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes treatments for cancer. The company's clinical stage drug candidates include RX-3117, which is in Phase II a clinical trial for the treatment of patients with relapsed or refractory pancreatic cancer and advanced bladder cancer; and Supinoxin that is in Phase II a clinical study to treat patients with metastatic triple negative breast cancer.

Further Reading: What is the LIBOR?

Receive News & Ratings for Rexahn Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rexahn Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.